NCT03082235

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: Eisai Inc. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

Study E6742-A001-001 is a randomized, double-blind, placebo-controlled, single ascending dose study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending oral doses of E6742 in healthy adult participants.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	E6742	gelatin capsules
DRUG	Placebo	gelatin capsules

Timeline

• Start date: 2017-03-03
• Primary completion: 2017-10-11
• Completion: 2017-10-11
• First posted: 2017-03-17
• Last updated: 2018-09-07

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study